-
1
-
-
84878185729
-
A critical analysis of the clinical use of incretin-based therapies: Are the glp-1 therapies safe?
-
Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36: 2118-2125.
-
(2013)
Diabetes Care
, vol.36
, pp. 2118-2125
-
-
Butler, P.C.1
Elashoff, M.2
Elashoff, R.3
-
2
-
-
84878808238
-
Pharmacology, physiology, and mechanisms of incretin hormone action
-
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837.
-
(2013)
Cell Metab
, vol.17
, pp. 819-837
-
-
Campbell, J.E.1
Drucker, D.J.2
-
3
-
-
84878352363
-
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors
-
Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-2604.
-
(2013)
Diabetes
, vol.62
, pp. 2595-2604
-
-
Butler, A.E.1
Campbell-Thompson, M.2
Gurlo, T.3
-
4
-
-
70350666371
-
Homozygous p86s mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor
-
Zhou C, Dhall D, Nissen NN, et al. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas. 2009;38:941-946.
-
(2009)
Pancreas
, vol.38
, pp. 941-946
-
-
Zhou, C.1
Dhall, D.2
Nissen, N.N.3
-
5
-
-
80051494742
-
Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice
-
Yu R, Dhall D, Nissen N, et al. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One. 2011; 6:e23397.
-
(2011)
PLoS One
, vol.6
-
-
Yu, R.1
Dhall, D.2
Nissen, N.3
-
6
-
-
84868638057
-
Glucagon receptor is required for long-term survival: A natural history study of the mahvash disease in a murine model
-
Yu R, Ren SG, Miroha J. Glucagon receptor is required for long-term survival: a natural history study of the Mahvash disease in a murine model. Endocrinol Nutr. 2012;59: 523-530.
-
(2012)
Endocrinol Nutr
, vol.59
, pp. 523-530
-
-
Yu, R.1
Ren, S.G.2
Miroha, J.3
-
7
-
-
0037417984
-
Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice
-
DOI 10.1073/pnas.0237106100
-
Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A. 2003;100:1438-1443. (Pubitemid 36184020)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.3
, pp. 1438-1443
-
-
Gelling, R.W.1
Du, X.Q.2
Dichmann, D.S.3
Romer, J.4
Huang, H.5
Cui, L.6
Obici, S.7
Tang, B.8
Holst, J.J.9
Fledelius, C.10
Johansen, P.B.11
Rossetti, L.12
Jelicks, L.A.13
Serup, P.14
Nishimura, E.15
Charron, M.J.16
-
8
-
-
77955920034
-
Regulation of acinar cell function in the pancreas
-
Williams JA. Regulation of acinar cell function in the pancreas. Curr Opin Gastroenterol. 2010;26:478-483.
-
(2010)
Curr Opin Gastroenterol
, vol.26
, pp. 478-483
-
-
Williams, J.A.1
-
9
-
-
84055193971
-
Pancreatic ductal cells in development, regeneration, and neoplasia
-
Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest. 2011;121:4572-4578.
-
(2011)
J Clin Invest
, vol.121
, pp. 4572-4578
-
-
Reichert, M.1
Rustgi, A.K.2
|